Nyt fra tidsskrifterne
Søgeord (tocilizumab) valgt.
101 emner vises.
1
Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial
BMC Infectious Diseases
Tilføjet 9.05.2025
2
Kaposi sarcoma herpesvirus (KSHV) inflammatory cytokine syndrome (KICS): a case study
BMC Infectious Diseases
Tilføjet 22.04.2025
3
Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial
Infection
Tilføjet 16.04.2025
4
Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry
Clinical Infectious Diseases
Tilføjet 2.04.2025
5
Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis
BMC Infectious Diseases
Tilføjet 4.01.2025
6
Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19
BMC Infectious Diseases
Tilføjet 18.10.2024
7
Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative
Critical Care Medicine
Tilføjet 13.10.2024
8
Acute necrotizing encephalopathy in adult patients with influenza: a case report and review of the literature
BMC Infectious Diseases
Tilføjet 10.09.2024
9
Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab
Infection
Tilføjet 2.09.2024
10
Pneumomediastinum and pneumoretroperitoneum after COVID-19: concealed intestinal perforation
BMC Infectious Diseases
Tilføjet 9.08.2024
11
Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan
PLoS One Infectious Diseases
Tilføjet 27.01.2024
12
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial
PLoS One Infectious Diseases
Tilføjet 30.12.2023
13
Comparative effectiveness of tocilizumab vs standard care in patients with severe COVID-19-related pneumonia: a retrospective cohort study utilizing registry data as a synthetic control
BMC Infectious Diseases
Tilføjet 7.12.2023
14
The impact of immunosuppressive therapy on secondary infections and antimicrobial use in COVID-19 inpatients: a retrospective cohort study
BMC Infectious Diseases
Tilføjet 18.11.2023
15
Comment on “Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection.”
Clinical Infectious Diseases
Tilføjet 9.11.2023
16
Vector autoregression: Useful in rare diseases?—Predicting organ response patterns in a rare case of secondary AA amyloidosis
PLoS One Infectious Diseases
Tilføjet 11.08.2023
17
Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signaling by reducing cell-free DNA in rheumatoid arthritis
Clinical & Experimental Immunology
Tilføjet 4.06.2023
18
Effectiveness of tocilizumab in non-intubated cases with COVID-19: a systematic review and meta-analysis
Infection
Tilføjet 11.05.2023
19
IL-6 blockade with tocilizumab diminishes indices of inflammation that are linked to mortality in treated HIV infection
Clinical Infectious Diseases
Tilføjet 4.04.2023
20
Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosis
BMJ Open
Tilføjet 24.03.2023
21
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
PLoS One Infectious Diseases
Tilføjet 6.03.2023
22
Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
BMJ Open
Tilføjet 25.02.2023
23
It Is Time to Determine Tocilizumab's Place in Coronavirus Disease 2019 (COVID-19)
Clinical Infectious Diseases
Tilføjet 10.02.2023
24
A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages
International Journal of Infectious Diseases
Tilføjet 2.02.2023
25
Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19
Critical Care Medicine
Tilføjet 25.12.2022
26
Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force
BMC Infectious Diseases
Tilføjet 13.12.2022
27
Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
BMC Infectious Diseases
Tilføjet 13.12.2022
28
Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study
BMJ Open
Tilføjet 6.12.2022
29
Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19
BMJ Open
Tilføjet 31.10.2022
30
Baricitinib versus tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: A prospective, investigational, real-world study
International Journal of Infectious Diseases
Tilføjet 31.10.2022
31
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
Clinical Microbiology and Infection
Tilføjet 20.10.2022
32
Tocilizumab as a Novel Therapy for Steroid-Dependent Polymyalgia Rheumatica
Journal of the American Medical Association
Tilføjet 20.09.2022
33
Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis
PLoS One Infectious Diseases
Tilføjet 19.09.2022
34
Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
Infection
Tilføjet 9.09.2022
35
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
PLoS One Infectious Diseases
Tilføjet 24.08.2022
36
Pembrolizumab in combination with tocilizumab in high-risk hospitalized COVID-19 patients (COPERNICO): A randomized proof-of-concept phase II study
International Journal of Infectious Diseases
Tilføjet 17.08.2022
37
Effect of Tocilizumab, Sarilumab, and Baricitinib on Mortality Among Patients Hospitalized for COVID-19 Treated with Corticosteroids: A Systematic Review and Meta-Analysis
Clinical Microbiology and Infection
Tilføjet 18.07.2022
38
Tocilizumab therapy for IL-6 increment in a patient with non-fatal severe fever with thrombocytopenia syndrome
International Journal of Infectious Diseases
Tilføjet 5.07.2022
39
'Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM' – Author’s reply
Clinical Microbiology and Infection
Tilføjet 4.07.2022
40
Re: 'early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM' by Broman et al
Clinical Microbiology and Infection
Tilføjet 20.06.2022
41
Risk factors associated with bacteremia in COVID-19 patients admitted to intensive care unit: a retrospective multicenter cohort study
Infection
Tilføjet 10.06.2022
42
Comparative-effectiveness research of COVID-19 treatment: a rapid scoping review
BMJ Open
Tilføjet 3.06.2022
43
The Safety and Efficacy of Tocilizumab in Older Adult Critically Ill Patients with Coronavirus Disease 2019 (COVID-19): A Multi-center, Cohort Study
International Journal of Infectious Diseases
Tilføjet 20.05.2022
44
Allocated but not treated: the silent 16%
Lancet
Tilføjet 6.05.2022
45
Flipped inflammatory time and the role of antibodies against SARS-CoV-2: optimising tocilizumab against COVID-19
Journal of Infectious Diseases
Tilføjet 19.03.2022
46
Epstein-Barr virus infection associated polymyositis and coronary artery dilation
BMC Infectious Diseases
Tilføjet 7.03.2022
47
Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM – A prospective, randomized, single center, open label study
Clinical Microbiology and Infection
Tilføjet 5.03.2022
48
Pneumococcal meningitis and COVID-19: dangerous coexistence. A case report
BMC Infectious Diseases
Tilføjet 24.02.2022
49
Another piece in the COVID-19 treatment puzzle
Lancet
Tilføjet 11.02.2022
50
Key summary of German national treatment guidance for hospitalized COVID-19 patients
Infection
Tilføjet 1.02.2022